PMID- 12772205
OWN - NLM
STAT- MEDLINE
DCOM- 20030624
LR  - 20171116
IS  - 0022-4790 (Print)
IS  - 0022-4790 (Linking)
VI  - 83
IP  - 2
DP  - 2003 Jun
TI  - Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma 
      before and after surgical treatment.
PG  - 112-5
AB  - BACKGROUND AND OBJECTIVES: Fas and its specific ligand (Fas-L), both of which are 
      involved in apoptosis, exist in membrane-bound and soluble forms. The soluble 
      forms (sFas and sFas-L) have been observed in various tumours, but their clinical 
      significance has not yet been clarified. The aim of this study was to assess 
      serum sFas and sFas-L levels in patients with laryngeal squamous cell carcinoma 
      (LSCC) and their possible correlations with surgical treatment. METHODS: Serum 
      sFas and sFas-L levels were determined by ELISA in samples taken from 26 LSCC 
      patients on the day before surgery (T0), and 2 weeks (T1) and 6 months after 
      surgery (T2), and in samples taken from 35 healthy volunteers. RESULTS: The mean 
      serum sFas levels in the 35 healthy volunteers and the 26 LSCC patients at T0 
      were respectively 5941 +/- 411 pg/ml and 6290 +/- 652 pg/ml (P = 0.63), and the 
      mean serum sFas-L levels were 0.1 +/- 0.05 ng/ml and 2.95 +/- 0.8 ng/ml (P < 
      0.0001). After surgery, there was a statistically significant decrease in sFas at 
      both T1 (P < 0.05) and T2 (P < 0.01), and in sFas-L at T2 (P < 0.01). 
      CONCLUSIONS: The decrease in sFas and sFas-L levels after surgery suggest that 
      they may be produced by or closely linked to tumour cells. Larger prospective 
      clinical studies of patients with LSCC will be needed to establish the clinical 
      significance of sFas and sFas-L, as reported for other neoplasms.
CI  - Copyright 2003 Wiley-Liss, Inc.
FAU - Pignataro, Lorenzo
AU  - Pignataro L
AD  - Department of Otorhinolaryngoiatric Sciences, IRCCS Polyclinic Hospital, 
      University of Milan, Milan, Italy. lorenzo.pignatoro@unina.it
FAU - Arisi, Elena
AU  - Arisi E
FAU - Sambataro, Giuseppe
AU  - Sambataro G
FAU - Corsi, Massimiliano Marco
AU  - Corsi MM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Surg Oncol
JT  - Journal of surgical oncology
JID - 0222643
RN  - 0 (FASLG protein, human)
RN  - 0 (Fas Ligand Protein)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (fas Receptor)
SB  - IM
MH  - Aged
MH  - Apoptosis
MH  - Carcinoma, Squamous Cell/*chemistry/pathology/*surgery
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Fas Ligand Protein
MH  - Female
MH  - Humans
MH  - Laryngeal Neoplasms/*chemistry/pathology/*surgery
MH  - Male
MH  - Membrane Glycoproteins/*blood
MH  - Solubility
MH  - fas Receptor/*blood
EDAT- 2003/05/29 05:00
MHDA- 2003/06/25 05:00
CRDT- 2003/05/29 05:00
PHST- 2003/05/29 05:00 [pubmed]
PHST- 2003/06/25 05:00 [medline]
PHST- 2003/05/29 05:00 [entrez]
AID - 10.1002/jso.10246 [doi]
PST - ppublish
SO  - J Surg Oncol. 2003 Jun;83(2):112-5. doi: 10.1002/jso.10246.